DIAGNOS Inc. (TSXV:ADK)
0.240
+0.005 (2.13%)
Apr 28, 2026, 3:29 PM EST
DIAGNOS Revenue
DIAGNOS had revenue of 15.21K CAD in the quarter ending December 31, 2025, a decrease of -41.61%. This brings the company's revenue in the last twelve months to 68.16K, down -46.50% year-over-year. In the fiscal year ending March 31, 2025, DIAGNOS had annual revenue of 103.80K, down -39.00%.
Revenue (ttm)
68.16K
Revenue Growth
-46.50%
P/S Ratio
423.99
Revenue / Employee
3.10K
Employees
22
Market Cap
28.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 103.80K | -66.36K | -39.00% |
| Mar 31, 2024 | 170.16K | -315.59K | -64.97% |
| Mar 31, 2023 | 485.75K | 46.92K | 10.69% |
| Mar 31, 2022 | 438.83K | 171.76K | 64.31% |
| Mar 31, 2021 | 267.07K | -64.44K | -19.44% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Principal Technologies | 370.42K |
| NexgenRx | 17.93M |
| Comprehensive Healthcare Systems | 5.79M |
| AI/ML Innovations | 125.47K |
| NetraMark Holdings | 165.26K |
| Seegnal | 1.72M |
| nDatalyze | 887.00 |
DIAGNOS News
- 20 days ago - DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA - GlobeNewsWire
- 27 days ago - DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration - GlobeNewsWire
- 7 weeks ago - DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants - GlobeNewsWire
- 2 months ago - DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 2 months ago - DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation - GlobeNewsWire
- 3 months ago - DIAGNOS Announces the Engagement of IBN - GlobeNewsWire
- 5 months ago - Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital - GlobeNewsWire
- 5 months ago - DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025 - GlobeNewsWire